DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to § 240.14a-12

Horizon Pharma Public Limited Company

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  1.  

Title of each class of securities to which transaction applies:

 

     

  2.  

Aggregate number of securities to which transaction applies:

 

     

  3.  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  4.  

Proposed maximum aggregate value of transaction:

 

     

  5.  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  1.  

Amount Previously Paid:

 

     

  2.  

Form, Schedule or Registration Statement No.:

 

     

  3.  

Filing Party:

 

     

  4.  

Date Filed:

 

     

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Shareholder Meeting to Be Held on April 30, 2020.

 

          

 

Meeting Information            

 

   
           Meeting Type:     Annual General Meeting    

HORIZON THERAPEUTICS PLC

        For holders as of:     February 25, 2020    
          

 

Date: April 30, 2020

 

 

      Time: 3:00 p.m. (local time)

   
          

 

Location:  Connaught House

   
          

  1st Floor

   
          

  1 Burlington Road Dublin 4

   
          

  D04 C5Y6, Ireland

   

LOGO

                
            

  HORIZON THERAPEUTICS PLC

  CONNAUGHT HOUSE

  1 BURLINGTON ROAD DUBLIN 4

  D04 C5Y6, IRELAND

    You are receiving this communication because you hold shares in the company named above.
   

 

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

    

LOGO

   

 

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

        

See the reverse side of this notice to obtain proxy materials and voting instructions.

 


   

 

Before You Vote  

    
          
      

How to Access the Proxy Materials

 

       
      Proxy Materials Available to VIEW or RECEIVE:    

 

 

 

 

 

 

 

 

 

 

   

 

 

 

 

    

 

 

PROXY STATEMENT         2019 ANNUAL REPORT TO SHAREHOLDERS

 

How to View Online:

Have the information that is printed in the box marked by the arrow    LOGO  (located on the following page) and visit: www.proxyvote.com.

 

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

 

                               1) BY INTERNET:         www.proxyvote.com

                               2) BY TELEPHONE:     1-800-579-1639

                               3) BY E-MAIL*:            sendmaterial@proxyvote.com

 

*  If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow   LOGO   (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before April 16, 2020 to facilitate timely delivery.

 

   
       
   

 

How To Vote  

    
          
      

Please Choose One of the Following Voting Methods

 

                

 

 

LOGO

   

 

 

 

 

 

Vote In Person: Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow   LOGO  (located on the following page) available and follow the instructions.

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 

   
             


Voting Items  

 

        

The Board of Directors recommends you vote
“FOR” each of the nominees for director listed

below and “FOR” Proposals 2, 3, 4, 5 and 6.

  1.      

Election of Class III Director Nominees:

 

   
    1a.   Gino Santini    
    1b.   James Shannon, M.D.      
    1c.   Timothy Walbert      
 
  2.  

Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020 and authorization of the Audit Committee to determine the auditors’ remuneration.

 

  3.   Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.
  4.   Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.
  5.   Approval of the 2020 Equity Incentive Plan.
  6.   Approval of the 2020 Employee Share Purchase Plan.
   
LOGO    


 

 

 

 

 

 

 

    

 

LOGO